Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT07446855 as recruiting, last updated 2026-10-01. Enrolment is 180 planned participants, an estimate. Interventions: AZD4956, Saruparib. Primary measures include Parts A and B: Number of participants with adverse events (AEs) and serious adverse events (SAEs); Part B: Progression free survival (PFS). No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Saruparib, PARP, AstraZeneca and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/